Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1- DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity

Journal of Immunology

Volumn 162, Issue 4, 1999, Pages 2432-2440

  Ågren, Lena C ^a   Ekman, Lena ^a   Löwenadler, Björn ^b   Nedrud, John G ^c   Lycke, Nils Y ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CTA1 DD; CYCLIC AMP; GANGLIOSIDE GM1; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; IMMUNOMODULATION; INTERNALIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; BINDING SITES, ANTIBODY; CHOLERA TOXIN; CYCLIC AMP; ENZYME ACTIVATION; ESCHERICHIA COLI; FEMALE; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINANT FUSION PROTEINS;

EID: 0033557754     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. MI-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur. J. Immunol. 28:1243.
2. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
3. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203.
4. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644.
5. Grant, C. C., R. J. Messer, and W. Cieplak, Jr. 1994. Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin. Infect. Immun. 62:4270.
6. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821.
7. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123.
8. S. Lycke, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:504.
9. Rappuoli, R., and M. Pizza. 1991. Structure and evolutionary aspects of ADP-ribosylating toxins. In Sourcebook of Bacterial Protein Toxins. J. E. A. a. J. H. Freer, ed. Academic Press, London, p. 1.
10. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
11. Merritt, E. A., and W. G. Hol. 1995. AB5 toxins. Curr. Opin. Struct. Biol. 5:165.
12. de Haan, L., W. R. Verweij, I. K. Feil, T. H. Lijnema, W. G. Hol, E. Agsteribbe, and J. Wilschut. 1996. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 64:5413.
13. Tsuji, T., T. Yokochi, H. Kamiya, Y. Kawamoto, A. Miyama, and Y. Asano. 1997. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology 90:176.
14. Ågren, L., L. Ekman, B. Löwenadler, and N. Lycke. 1997. A genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158:3936.
15. Elson, C. O. 1996. Cholera toxin as a mucosal adjuvant. In Mucosal Vaccines. Academic Press, Inc., New York.
16. Guidry, J. J., L. Cardenas, E. Cheng, and J. D. Clemens. 1997. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect. Immun. 65:4943.
17. Nashar, T. O., H. M. Webb, S. Eaglestone, N. A. Williams, and T. R. Hirst. 1996. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl. Acad. Sci. USA 93:226.
18. Holmgren, J. 1981. Actions of cholera toxin and the prevention and treatment of cholera. Nature 292:413.
19. Field, M., M. C. Rao, and E. B. Chang. 1989. Intestinal electrolyte transport and diarrheal disease. N. Engl. J. Med 321:800.
20. Moss, J., and M. Vaughan. 1988. ADP-ribosylation of guanine nucleolide-binding regulatory proteins by bacterial toxins. Adv. Enzymol. 61:303.
21. Donaldson, J. G., and R. D. Klausner. 1994. ARF: a key regulatory switch in membrane traffic and organelle structure. Curr. Opin. Cell Biol. 6:527.
22. Moss, J., and M. Vaughan. 1995. Structure and function of ARF proteins: Activators of cholera toxin and critical components of intracellular vesicular transport processes. J. Biol. Chem. 270:12327.
23. Sofer, A., and A. H. Futerman. 1996. Rate of retrograde transport of cholera toxin from the plasma membrane to the Golgi apparatus and endoplasmic reticulum decreases during neuronal development. J. Neurochem. 67:2134.
24. Mekalanos, J. J. 1983. Duplication and amplification of toxin genes in Vibrio cholerae. Cell 35:253.
25. Jendeberg, L., B. Persson, R. Andersson, R. Karlsson, M. Uhlen, and B. Nilsson. 1995. Kinetic analysis of the interaction between protein A domain variants and human Fc using plasmon resonance detection. J. Mol. Recognit. 8:270.
26. Cedergren, L., R. Andersson, B. Jansson, M. Uhlen, and B. Nilsson. 1993. Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng. 6:441.
27. Sanger, F., S. Niclen, and A. R. Coulson. 1977. DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463.
28. Bromander, A. K., L. Ekman, M. Kopf, J. G. Nedrud, and N. Y. Lycke. 1996. IL-6 deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J. Immunol. 156:4290.
29. Tsuji, T., T. Inoue, A. Miyama, and M. Noda. 1991. Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity. FEBS Lett. 291:319.
30. Francis, M. L., I. Okazaki, J. Moss, A. Kurosky, L. M. Pecanha, and J. J. Mond. 1995. cAMP-independent effects of cholera toxin on B cell activation. III. Cholera toxin A subunit-mediated ADP-ribosylation acts synergistically with ionomycin or IL-4 to induce B cell proliferation. J. Immunol. 154:4956.
31. Rankin, P. W., E. L. Jacobson, R. C. Benjamin, J. Moss, and M. K. Jacobson. 1989. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J. Biol. Chem. 264:4312.
32. 2: separation of affinity from specificity. Mol. Immunol. 30:1279.
33. Klaus, G. G., K. Vondy, and M. Holman. 1987. Selective effects of cholera toxin on the activation of mouse B cells by different polyclonal activators. Eur. J. Immunol. 17:1787.
34. Elson, C. O., and M. T. Dertzbaugh. 1994. Mucosal adjuvants. In Handbook of Mucosal Immunology. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, and J. Bienenstock, eds. Academic Press, San Diego, p. 391.
35. Douce, G., M. Pizza, M. Roberts, R. Rappuoli, and G. Dougan. 1998. Mutant pertussis and Escherichia coli heat-labile toxins as adjuvants for enhancing local and systemic immune responses to coadministered, nonliving antigens. In New Generation Vaccines. G. C. W. M. M. Levine, J. B. Kaper, and J. S. Cobon, eds. Marcel Dekker, New York, p. 253.
36. MI-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. Immunol. Cell Biol. 76:270.
37. Blanchard, T. G., N. Lycke, S. J. Czinn, and J. Nedrud. 1998. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against H. felis. Immunology 93:22.
38. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 39:301.
39. Van der Heijden, P. J., A. T. Bianchi, M. Dol, J. W. Pals, W. Stok, and B. A. Bokhout. 1991. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice. Immunology 72:89.
40. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277.
41. Moss, J., and M. Vaughan. 1995. Structure and function of ARF proteins: activators of cholera toxin and critical components of intracellular vesicular transport processes. J. Biol. Chem. 270:12327.
42. Hajishengallis, G., S. K. Hollingshead, T. Koga, and M. W. Russell. 1995. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 154:4322.
43. Magagnoli, C., R. Manetti, M. R. Fontana, V. Giannelli, M. M. Giuliani, R. Rappuoli, and M. Pizza. 1996. Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin. Infect. Immun. 64:5434.
44. Russell, M. W., and H.-Y. Wu. 1991. Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect. Immun. 59:4061.
45. Tamura, S., Y. Samegai, H. Kurata, T. Nagamine, C. Aizawa, and T. Kurata. 1988. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6:409.
46. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, K. Fujihashi, F. W. Van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267.
47. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56:1748.
48. Michetti, P., C. Kreiss, K. Kotloff, N. Porta, J. L. Blanco, D. Bachman, P. F. Sadlinger, I. Corthesy-Theulaz, G. Losonsky, R. Nichols, M. Stolte, T. Monath, S. Ackerman, and Blum. 1997. Oral immunization of H. pylori infected adults with recombinant urease and LT adjuvant. Gastroenterology 112: A1042 (Abstr.).
49. Conference Coverage (Interscience Conference on Antimicrobial Agents and Chemotherapy). 1997. Vaccine Wkly. p. 4.
50. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clemens. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510.
51. Zhang, R. G., D. L. Scott, M. L. Westbrook, S. Nance, B. D. Spangler, G. G. Shipley, and E. M. Westbrook. 1995. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol. 251:563.